As the most challenging disease to spell and pronounce continues its global expansion, access to the only approved chikungunya virus vaccine is becoming broader.
The Coalition for Epidemic Preparedness Innovations (CEPI) has expanded its support to provide expanded access to the world’s first chikungunya vaccine, IXCHIQ®.
IXCHIQ (VLA1553) is a monovalent, single-dose, live-attenuated chikungunya vaccine that the U.S. Food and Drug Administration approved in November 2023.
$41.3 Million Supports Increased Access to the First Chikungunya Vaccine
Two Mosquito-Transmitted Viruses Causing Microcephaly in Newborns
According to the Pan American Health Organization (PAHO), scientists in Brazil believe that the Oropouche virus (OROV) may cause stillbirths and neurological defects in babies who are infected in the womb, similar to the Zika virus.
Since 2013, 31 countries and territories in the Americas have reported cases of microcephaly (head shape issues) and other central nervous system malformations associated with Zika infection.